We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+20.56%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$4.36B
AUM Growth
+$814M
Cap. Flow
+$435M
Cap. Flow %
9.98%
Top 10 Hldgs %
53.12%
Holding
130
New
25
Increased
23
Reduced
18
Closed
26

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$183M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$135M
3
ATNX
Athenex, Inc. Common Stock
ATNX
+$65.5M
4
NVRO
NEVRO CORP.
NVRO
+$44.9M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$37.8M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$89.6M
2
ASND icon
Ascendis Pharma A/S
ASND
+$76.6M
3
NVTA
Invitae Corporation
NVTA
+$17.6M
4
IRTC icon
iRhythm Holdings
IRTC
+$15M
5
ZGNX
Zogenix, Inc.
ZGNX
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Financials 0.76%
3 Technology 0.14%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RMTI icon
76
Rockwell Medical
RMTI
$27.2M
$4.51M 0.1%
+13,636
New +$6.92M
HSACU
77
DELISTED
Health Sciences Acquisitions Corporation Units
HSACU
$4.24M 0.1%
+400,000
New +$4.17M
TWST icon
78
Twist Bioscience
TWST
$5.32B
$3.22M 0.07%
+110,856
New +$2.93M
VERU icon
79
Veru
VERU
$35.5M
$3.08M 0.07%
144,500
+2,000
+1% +$33.9K
GRCE
80
Grace Therapeutics
GRCE
$33.8M
$2.03M 0.05%
37,081
– –
AORT icon
81
Artivion
AORT
$1.34B
$1.5M 0.03%
50,000
– –
SRRA
82
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.49M 0.03%
66,655
– –
EIGR
83
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.48M 0.03%
4,663
– –
AXSM icon
84
Axsome Therapeutics
AXSM
$11.7B
$1.39M 0.03%
53,879
– –
RACE icon
85
Ferrari
RACE
$67.8B
$1M 0.02%
6,200
– –
VYGR icon
86
Voyager Therapeutics
VYGR
$181M
$996K 0.02%
+36,573
New +$837K
MDCO
87
DELISTED
Medicines Co
MDCO
$712K 0.02%
+19,532
New +$638K
ABEOW
88
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
$620K 0.01%
659,636
– –
GH icon
89
Guardant Health
GH
$19.1B
$571K 0.01%
+6,617
New +$505K
LAB icon
90
Standard BioTools
LAB
$342M
$567K 0.01%
46,030
– –
ALNA
91
DELISTED
Allena Pharmaceuticals
ALNA
$538K 0.01%
132,300
– –
TCRT icon
92
Alaunos Therapeutics
TCRT
$4.64M
$528K 0.01%
+603
New +$415K
MREO
93
Mereo BioPharma
MREO
$48.9M
$452K 0.01%
+179,419
New +$785K
TNDM icon
94
Tandem Diabetes Care
TNDM
$1.27B
$414K 0.01%
6,422
-6,422
-50% -$414K
NTRA icon
95
Natera
NTRA
$36.4B
$401K 0.01%
+14,549
New +$321K
XBI icon
96
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$70K ﹤0.01%
+200,000
New +$17.1M
BIIB icon
97
CALL
Biogen
BIIB
$30.9B
$65K ﹤0.01%
200,000
-200,000
-50% -$46.2M
OTLKW
98
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$46K ﹤0.01%
420,875
– –
SLDB icon
99
CALL
Solid Biosciences
SLDB
$792M
$23K ﹤0.01%
+13
New +$1.42K
ABEO icon
100
Abeona Therapeutics
ABEO
$355M
– –
-7,232
Closed -$1.33M
1 2 3
4
5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2019 Portfolio in Review

As of Q2 2019, Perceptive Advisors held 130 positions worth $4.36B, up 23% from $3.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Perceptive Advisors deployed $435M of net new capital in Q2 2019, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was BridgeBio Pharma: 6,706,268 shares worth $181M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $89.6M trimmed.

  • Perceptive Advisors's largest Q2 2019 buy was BridgeBio Pharma: 6,706,268 shares worth $181M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q2 2019, an estimated $135M increase.
  • Perceptive Advisors's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $89.6M.
  • Perceptive Advisors fully exited iRhythm Holdings in Q2 2019, selling an estimated $15M.
  • Perceptive Advisors's ten largest holdings make up 53% of its $4.36B portfolio in Q2 2019.
  • Perceptive Advisors opened 25 new positions and closed 26 in Q2 2019.
  • Perceptive Advisors's portfolio value rose 23% quarter-over-quarter to $4.36B.

Based on Perceptive Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.